The company has been in negotiations for the distribution and marketing rights with several regional, national and international firms who have sought out potential licensing for territorial distribution.
In Europe a form of the gum, yet to be officially named, will undergo clinical testing this summer as one of the stages necessary for eventual European FDA approval. This medication will consist of a combination of cannabinoid based compounds. The indications for use would include patients with chronic pain, muscular spasticity from multiple sclerosis, and nausea management from side effects of chemotherapy in cancer patients. The company has allocated this year twelve ($12m) million dollars in company equity to secure the clinical development of this product.
Rebranding of CanChew Biotechnologies Corporate Website to be completed in April, which includes: The clinical development path with timelines and interactive update modules, additional and expanded research library.
Rebranding and launch of the Canchew over the counter product sales and informational website, which includes: Canchew Store front and shopping carts, expanded social media and blog components, store availability tracker and locator, additional subscription options for clients in need of a larger supply of Canchew advantage CBD chewing gum.
Canipa Holdings – Set up in 2012 to handle the marketing, sales and distribution of Medical Marijuana Inc.'s portfolio of products throughout Europe and the European Union Trade Zone participant counties. This year we hav
|SOURCE Medical Marijuana, Inc.|
Copyright©2012 PR Newswire.
All rights reserved